Clinical Study

Effect of Sulodexide on Urinary Biomarkers of Kidney Injury in Normoalbuminuric Type 2 Diabetes: A Randomized Controlled Trial

Table 2

Changes from baseline metabolic parameters.

ParametersSulodexide ()Placebo () value

Baseline BW (kg)72.9 ± 13.5966.16 ± 13.110.119
 Change at end point (mmHg)0.24 ± 1.04−0.36 ± 1.440.144
Baseline SBP (mmHg)128.8 ± 6.89129 ± 12.010.949
 Change at end point (mmHg)−1.25 ± 10.47−2.6 ± 15.010.743
Baseline DBP (mmHg)73.85 ± 8.3776.65 ± 8.160.291
 Change at end point (mmHg)−1.6 ± 9.48−2.15 ± 8.940.851
Baseline FPG (mg/dL)133.4 ± 31.29142.38 ± 33.850.389
 Change at end point (mg/dL)1.65 ± 60.851.73 ± 42.350.818
Baseline HA1C (%)7.41 ± 1.636.89 ± 0.940.232
 Change at end point (%)−0.1 ± 1.49−0.05 ± 0.660.897
Baseline LDL (mg/dL)86.8 ± 31.3991.75 ± 31.770.623
 Change at end point (mg/dL)−4.05 ± 34.51−2.6 ± 26.240.882

Data are mean SD; week 14 values compared with baseline.